PeptideStack
5.2kquestions
20kanswers
220users

Is SURMOUNT-1 a fair comparison of a GLP-1 receptor agonist against its comparator arm?

Asked 12 Apr 2025Modified 16 months agoViewed 10k times
18

Setup, so nobody has to ask: SURMOUNT-1 · a GLP-1 receptor agonist.

This has the shape of a fact but I cannot find its origin.

What I found instead were three secondary sources all citing each other.

Has anyone verified this independently?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
CC
askedcake_collapsed13k2812 Apr 2025

No answers yet

This question has not been answered. It has been viewed 10k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.